Switzerland Incyte’s Jonathan Dickinson discusses the company’s mission to address unmet medical needs in oncology and autoimmune diseases while expanding its footprint across Europe. He highlights the strategic role of Incyte’s internal research, clinical trials, and recent product launches, along with their ambitions to double European revenues in the coming years.…
Ichnos Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals and the licensing agreement Ichos has with Almirall for the IL-1RAP antagonist, ISB 880. … the Ichnos team has further…
pharma The CEO and founder of ModiQuest discusses how, with its unique, fully-integrated antibody generation and development platform, the company is developing antibodies for potentially groundbreaking therapies for the prevention and treatment of rheumatoid arthritis and growing its already well-established CRO arm serving clients from around the world. Could you introduce…
pharma Ileana Quiñones, president and general manager of iPR-AstraZeneca, discusses the clear strategy of the affiliate in being a leading manufacturer in Puerto Rico and the steps necessary to ensure their place in the country and within the AstraZeneca organization. Where is AstraZeneca focused today and how does the Puerto Rican…
See our Cookie Privacy Policy Here
